BioXcel Therapeutics (FRA:BX2) COGS-to-Revenue : 5.46 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics COGS-to-Revenue?

BioXcel Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2024 was €1.05 Mil. Its Revenue for the three months ended in Sep. 2024 was €0.19 Mil.

BioXcel Therapeutics's COGS to Revenue for the three months ended in Sep. 2024 was 5.46.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. BioXcel Therapeutics's Gross Margin % for the three months ended in Sep. 2024 was -446.11%.

BioXcel Therapeutics COGS-to-Revenue Historical Data

The historical data trend for BioXcel Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics COGS-to-Revenue Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.05

0.91

BioXcel Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
COGS-to-Revenue	Get a 7-Day Free Trial															1.50	1.90	0.14	0.06	5.46

BioXcel Therapeutics COGS-to-Revenue Calculation

BioXcel Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.155	/	1.265
	=	0.91

BioXcel Therapeutics's COGS to Revenue for the quarter that ended in Sep. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.054	/	0.193
	=	5.46

BioXcel Therapeutics (FRA:BX2) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

BioXcel Therapeutics's Gross Margin % for the three months ended in Sep. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1.054 / 0.193
	=	-446.11 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

BioXcel Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

BTAI:USA

Address

555 Long Wharf Drive, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics Headlines

No Headlines